
Virtual Abortion Care Is a Lifeline, Not a Safety Net
New data from the Guttmacher Institute shows that more people are turning to virtual abortion care—and while that tidbit might sound like a silver lining in our post- Roe world, it can be dangerously misleading if we're not careful.
Telehealth is, without a doubt, an essential tool. My organization was one of the first abortion providers in the country to offer telemedicine back in 2009. And since the FDA allowed abortion pills to be delivered by mail in 2021, we have worked tirelessly to expand our virtual abortion care into 10 states to reach as many patients as possible. But let's be clear: virtual care alone isn't a silver bullet. And it's not a stand-in for truly accessible care.
The best abortion care is about the both/and, eschewing the tyranny of either/or. True access looks like real options for abortion seekers, whether that's in our clinic or the comfort of their own space. We need both. After all, abortions after 12 weeks are provided in clinics, so focusing only on pills and telemedicine neglects patients who are further into their pregnancies or who require a larger range of pain-management options.
The increase in online-only abortion provision speaks to the critical role that virtual providers play in a time of escalating bans and shrinking access. Where it's available, telehealth can lower barriers by reducing travel time, cutting costs, and lessening the stigma people can feel when pushing through protesters to seek abortion care in person. But this is only part of the story.
The reality is, the Guttmacher numbers showed the majority of abortions last year still took place in brick-and-mortar clinics. That's a crucial detail because despite the headlines and hope around telemedicine, most people still rely on in-person care. And for those living in the 16 states with total or near-total abortion bans, virtual care isn't always attainable, as they still need to leave the state entirely. Accessing virtual abortion care also isn't as simple as clicking a link. You need a device, an internet connection, a credit card, and—critically—a safe place to receive the pills. For someone experiencing domestic violence, housing insecurity, or financial instability, those requirements can be just as insurmountable as making it to a clinic.
Every day, our in-clinic clinicians and virtual-care providers work closely with patients navigating an increasingly fractured and costly system. And too often, those hit hardest are Black and Latina women, young people, and people working hourly-wage jobs without paid leave. Based on Guttmacher data and our own patients' experience, we see a clear preference for in-person care among our patients of color, while our virtual care skews more white and Asian. That alone should challenge assumptions that telemedicine is an option for everyone.
Fewer and fewer travelers can afford to make it to abortion care in other states. More are having to delay care, or forgo it entirely. And yet none of the recent reporting on abortion access, including the Guttmacher data and the viral New York Times maps, has factored in the impact of funding.
For example, immediately after the Dobbs decision overturning Roe, The Abortion Access Fund (TAF) operated by Resources for Abortion Delivery (RAD) stepped in to cover the full cost of abortion care for people traveling from ban states to access points like Illinois, Colorado, Florida, North Carolina, and New Mexico. Support like that was a game changer. It provided no-cost procedures and freed up grassroots and local abortion funds to focus on covering travel, lodging, and other practical support.
But that support ended in September 2024, and this followed large cuts from the National Abortion Federation Justice Fund that went from funding our patients in poverty at 50% down to 30% in July of the same year. The effects of these cuts have been immediate. While existing abortion funds still do incredible work, they're under immense strain. And without that extra layer of funding, far fewer patients can travel or get the full scope of care they need. For many, the question of whether they can access abortion at all—let alone where or how—now comes down to what they can afford. We simply cannot ignore how the economic landscape has shifted with the devastating loss of that additional support.
Let's not forget: people should be able to use their insurance or Medicaid to pay for abortion care, not solely rely on donations or emergency grants. Donation dollars should not be used for care that Medicaid and insurance could easily cover. It's why we navigate the sticky red tape to accept insurance and Medicaid for patients in as many states as possible, but ultimately, reimbursement systems are patchy, and far too many people live in places where public or private coverage can't be used for abortion care at all.
As independent abortion providers, we are doing everything we can. We have dedicated staff whose only job is to help patients access every dollar of funding available. On any given day, we're coordinating between $5,000 and $10,000 in financial support for our patients. That's six days a week, 52 weeks a year. But with national abortion funds unable to provide as much money and local grassroots funds stretched to their limits, it's just never enough.
When people talk about telemedicine as the solution, they often overlook these financial realities. They also underestimate the practical support required to make access real. Even if funding were magically available to cover 100% of a patient's abortion procedure, that means little if they can't afford a tank of gas to leave their state, find a hotel room, or arrange childcare for their kids back home. These are the underfunded infrastructures we urgently need.
To build a future where abortion is truly accessible, we must prioritize economic justice, invest in the infrastructure that supports patients on the move, and center the people most impacted by bans and barriers. That means investing in in-clinic care and virtual care. It means Medicaid and mutual aid. Anything less risks reinforcing the very inequities we're trying to dismantle.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Black Kids Are 5 Times More Likely to Get Severe COVID. Now Vaccines Are Being Cut.
The Trump administration has declared an end to COVID-19 vaccine recommendations for children and pregnant people, and health experts have a warning: This is a threat to Black communities. U.S. Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the Centers for Disease Control and Prevention, announced the decision on May 27 and said vaccine guidance would now focus solely on adults over 65 and those with high-risk conditions, effective immediately. By June 3, Dr. Lakshmi Panagiotakopoulos stepped down from her role helping lead the agency's COVID-19 vaccine advisory group, saying she could no longer support decisions that put pregnant people and children at risk. Before the changes took effect, COVID-19 vaccines were recommended for anyone 6 months and older. Kennedy did not offer a scientific rationale for the new recommendations. For Black Americans, the policy shifts are more than bureaucratic changes, according to Oni Blackstock, a physician and founder of Health Justice, a racial and health equity consulting practice. 'These new guidelines don't exist in a vacuum,' she said. 'Limiting booster eligibility risks further compromising the already fragile health status of many Black Americans.' Black Americans are 1.5 times more likely to contract COVID-19 and four times more likely to be hospitalized, according to the Centers for Medicare & Medicaid Services. Research from the Center for Primary Care at Harvard Medical School found that Black children are more than five times as likely to die from the virus. An estimated 165,000 to 220,000 Black Americans have died from COVID-19, according to data compiled by the APM Research Lab. According to a 2023 report from the U.S. Census Bureau, nearly 32% of Black Americans who contracted COVID-19 also experienced long COVID symptoms. The U.S. Food and Drug Administration cited a lack of evidence that annual boosters are needed by healthy, low-risk adults. However, Blackstock, a primary care and HIV physician, said the policy change marks a significant departure from past years when vaccines were broadly recommended and federally funded. 'This contradicts recent CDC data showing that the 2024–2025 boosters benefit people 18 years and older, especially early after vaccination,' she added. Blackstock noted that many Black Americans already struggle with health care access due to systemic barriers like a lack of insurance and residential segregation. 'When these combine with more restrictive vaccine guidelines,' she said, 'it becomes even harder for Black Americans to get boosters and worsens existing health disparities.' These barriers also deepen historic mistrust in health care, said Jerry Abraham, a family and community medicine physician. Abraham, who is director of the CDU-KEDREN Mobile Street Medicine program in Los Angeles, said the history of medical racism and continued treatment disparities fuel skepticism toward public health. Even as boosters offer real benefits, he said, many remain hesitant or disconnected from resources that ensure protection. 'If children and pregnant women are no longer recommended for vaccination, will grandma still go to CVS and get it herself?' he said. Abraham added that in an era where health care professionals can no longer trust the updated guidelines from federal agencies, it's deeply concerning and a reminder that Black communities must once again rely on themselves. For answers about what comes next, read on. Aisha Harris, a family medicine physician in Flint, Michigan, told Capital B that limiting access to COVID-19 vaccines for healthy adults exposes high-risk groups like seniors and those who are immunocompromised. 'Reduced protection in healthy people increases their risk of being infected by COVID and of being a carrier,' said Harris, who owns the direct primary care clinic Harris Family Medicine. 'When more people are contagious, with or without symptoms, they have a higher chance of infecting others around them, including in their household or those they are taking care of as caregivers.' She warned this undermines community immunity. Without widespread coverage, even eligible groups face elevated risks. FDA officials say the new approach mirrors those taken by Australia and several European nations that limit vaccines to older or high-risk adults. But some critics argue the shift ignores U.S. disparities and bypasses standard CDC procedures. You can pay out of pocket, but it could cost up to $200. If the CDC doesn't recommend vaccines, Abraham said health plans are much less likely to cover them, since insurers typically follow CDC guidance. Yes, COVID-19 vaccines have already undergone extensive clinical trials before being authorized for public use. The FDA says it will require longer clinical trials before approving updated shots for healthy kids and adults, with studies lasting at least six months, likely delaying fall approvals. The CDC's vaccine advisory committee is expected to vote on fall vaccine recommendations in late June, but it's unclear how much influence it will have over the newly announced changes. High-risk conditions for COVID-19 vaccine eligibility generally include chronic kidney disease, chronic lung diseases, asthma, diabetes, immunocompromised states (from cancer treatment, organ transplant, HIV, etc.), heart conditions, Alzheimer's disease, obesity, sickle cell disease, smoking, and stroke or cerebrovascular disease. Yes. Studies show COVID-19 vaccination, including boosters, reduces the risk of severe illness and may lower the chances of developing long COVID symptoms after infection. The post Black Kids Are 5 Times More Likely to Get Severe COVID. Now Vaccines Are Being Cut. appeared first on Capital B News.
Yahoo
27 minutes ago
- Yahoo
FDA approves YolTech's YOLT-101 for familial hypercholesterolemia
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). YOLT-101 is an in vivo base editing therapy designed to target proprotein convertase subtilisin/kexin type 9 (PCSK9). Its innovative approach lies in its potential to durably reduce blood low-density lipoprotein cholesterol (LDL-C) levels through a single-dose treatment. The technology behind YOLT-101 incorporates YolTech's adenine base editor, known as hpABE5, which consists of nCas and a new deaminase evolved from Hafnia paralvei. To deliver this therapeutic agent, the company employs an advanced lipid nanoparticle (LNP) delivery system. hpABE5 can perform precise A•T to G•C base conversions without inducing DNA double-strand breaks, thus minimising risks associated with chromosomal abnormalities and off-target effects. YolTech Therapeutics co-founder and CEO Yuxuan Wu stated: 'The FDA IND clearance marks a significant milestone for YolTech. In vivo gene editing represents a new generation of therapeutics — offering one-time, durable solutions for chronic and genetic diseases. 'We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases.' Currently under evaluation in an ongoing investigator-initiated trial (IIT), YOLT-101 has shown promising results with a favourable safety profile and substantial LDL-C–lowering effects. Familial hypercholesterolemia is a genetic disorder stemming from mutations affecting LDL metabolism-related genes such as LDLR, Apolipoprotein B (APOB) and PCSK9. Individuals suffering from FH typically experience elevated LDL-C levels, which contribute to a heightened risk of developing early-onset atherosclerotic cardiovascular diseases. "FDA approves YolTech's YOLT-101 for familial hypercholesterolemia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio


UPI
38 minutes ago
- UPI
Celebrity diagnoses underscore rising breast cancer rates in young women
June 9 (UPI) -- More young women in the United States are being diagnosed with breast cancer, and several celebrities have helped raise awareness by sharing their stories. Singer Jessie J, 37, said last week that she has early-stage breast cancer and will have surgery this month. "Bachelorette" star Katie Thurston, 34, is documenting her treatment for stage 4 breast cancer. Actress Danielle Fishel, 43, also shared her diagnosis last summer, NBC News said in a new report. The rise in cases reflects a national trend. Between 2012 and 2021, breast cancer rates rose 1.4% each year in women under 50, compared with 0.7% each year in those 50 and older. Rates have increased across all racial and ethnic groups, especially among Asian American and Pacific Islander women under 50. Their breast cancer rates have jumped nearly 50% since 2000. Black women are more likely than other groups to be diagnosed with breast cancer before age 40, and they are also more likely to die from the disease, NBC News said. Routine mammograms usually start at age 40, and younger women are rarely screened unless they're at high risk - such as those with a family history or certain genetic mutation. Doctors say this delay in screening can make it harder to catch breast cancer early, when it is easier to treat. "The thought was always, if you had a change in your breast but you were a young woman, it was probably nothing," said Dr. Rani Bansal of Duke University School of Medicine. "As we're seeing more and more younger women get diagnosed ... we need to take these cases seriously." Symptoms to watch for include lumps or nipple discharge. Dr. Oluwadamilola Fayanju, chief of breast surgery at Penn Medicine, said her youngest breast cancer patient was just 17. She said young women should consider getting care at a clinic that specializes in breast imaging. Experts suspect many factors may play a role, including: • Hormones • A diet high in processed foods • Obesity • Increased alcohol use • Exposure to harmful chemicals Environmental toxins like BPA and Teflon have been widely used for decades. Researchers are now studying how those early exposures might raise cancer risk later on, NBC News reported. Some studies suggest that chemical hair straighteners ---often used by Black women -- may increase breast cancer risk, possibly by affecting hormones in the body. Delaying childbirth may also play a role. Women who have babies later in life are more likely to develop postpartum breast cancer - cancers that appear within five to 10 years of giving birth. Each year, about 18,000 U.S. women are diagnosed with postpartum breast cancer, said Dr. Virginia Borges of the University of Colorado Cancer Center. Younger women are more likely to be diagnosed with triple-negative breast cancer, a fast-growing type that has fewer treatment options. Even though overall survival rates are improving, Borges said breast cancer diagnosed before age 35 often spreads more easily. Doctors are still trying to understand why. "We need more data to better tailor our treatments towards younger women," Bansal added. "A lot of the studies that are done are in older women." Experts suggest that women who are at higher risk begin screenings as early as age 30. This may include yearly mammograms and breast MRIs. More information The American Cancer Society has more on breast cancer screening guidelines. Copyright © 2025 HealthDay. All rights reserved.